ECCO CONFER Cases Round 4: Call for similar cases
Deadline: June 29, 2018
Call for similar cases Round 3, Case 1: Pneumocystis jiroveci pneumonia in IBD patients treated with any type of immunomodulator(s) - deadline extended: June 29, 2018
Call for similar cases Round 3, Case 3: Inflammatory cutaneous lesions in IBD treated with ustekinumab and vedolizumab – deadline extended: June 29, 2018
Unique and extraordinary clinical cases are generally reported in the form of a single case report or a small series, making it hard to derive clinical conclusions on modes of presentation, diagnosis, and treatment.
ECCO CONFER Cases is an initiative to continuously identify, assemble, and report rare IBD cases of clinical relevance. By joining forces of the many members and supporters of ECCO, a joint report of all similar such cases can result in a large case series that will advance our knowledge on these uncommon patients.
A call will be made once a year to all ECCO Members to propose CONFER case projects. Cases should correspond to 4 main themes of interest:
Two to four cases will be selected by the CONFER steering committee.
The proposing investigator will act as PI and develop his/her case into a CONFER case project with the steering committee.
A call will then be made to all ECCO Members and affiliates who have encountered a similar case to contribute their case to the CONFER case series.
All received cases will be joined into a case series by a PI and prepared for publication.
3 manuscripts from Round 1 and 1 manuscript from Round 2 have already been published/accepted for publication in JCC and 1 manuscript from phase 3 is currently in the process of being drafted! Further information will be available in due time...
ECCO CONFER is managed by a four-member steering committee. The current steering committee is composed of:
Uri Kopylov (Israel)
Gionata Fiorino (Italy)
Konstantinos Karmiris (Greece)
Shaji Sebastian (United Kingdom)
The steering committee’s term will be 2 years, after which a new 4 member team will be elected by SciCom.
All contributing investigators will be acknowledged as collaborating authors, and the 10 who contributed most patients will be acknowledged as co-authors. When equal contributions occur, authorship status will be determined by temporal precedence in case contribution. The PI and the steering committee member who developed each case project and its publication will be the first and last author, respectively.
As per an ECCO Governing Board decision, submission to JCC would take precedence, unless a very high impact journal is deemed appropriate for publication.